DDInter610 DDInter1147
Durvalumab is a human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody and a novel immune-checkpoint inhibitor for cancer treatment. Produced by recombinant DNA technology in Chinese Hamster Ovary (CHO) cell suspension culture, durvalumab is a programmed death-ligand 1 (PD-L1) blocking antibody that works to promote normal immune responses that attack tumour cells.[L12621,L12627] Durvalumab is marketed under the brand name Imfinzi, which is available for intravenous injections. It was granted accelerated approval by the FDA in May 2017 for the treatment of selected patients with locally advanced or metastatic urothelial carcinoma. In September 2018, durvalumab was approved by the EMA for the treatment of adult patients with locally advanced, unresectable non-small cell lung cancer (NSCLC), only if PD-L1 is expressed in ≥ 1%
Meningococcal group C polysaccharide is group-specific polysaccharide antigens extracted and purified from *Neisseria meningitidis* serogroup C. *N. meningitidis* is a bacteria that causes endemic and epidemic diseases including meningitis and meningococcemia. It is subcutaneously administered as an active immunization against the invasive meningococcal disease caused by the serogroup C.
Durvalumab {u} may cause a minor interaction that can limit clinical effects when taken with {v} Vitamin E
Durvalumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Hydrocortisone
Durvalumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ocrelizumab
Durvalumab {u} may lead to a major life threatening interaction when taken with {v} Tofacitinib
Durvalumab {u} may lead to a major life threatening interaction when taken with {v} Baricitinib
Durvalumab may cause a minor interaction that can limit clinical effects when taken with Vitamin E
Durvalumab may cause a moderate interaction that could exacerbate diseases when taken with Hydrocortisone
Durvalumab may cause a moderate interaction that could exacerbate diseases when taken with Ocrelizumab
Durvalumab may lead to a major life threatening interaction when taken with Tofacitinib
Durvalumab may lead to a major life threatening interaction when taken with Baricitinib